The 4 analysts offering 12-month price forecasts for Lyell Immunopharma Inc have a median target of 15.50, with a high estimate of 21.00 and a low estimate of 15.00. The median estimate represents a +288.47% increase from the last price of 3.99.
The current consensus among 4 polled investment analysts is to Buy stock in Lyell Immunopharma Inc. This rating has held steady since March, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.28
Reporting Date Jun 01
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.